Pharma Mar S.A. deal

The Pasteur Institute (Paris) agreed to evaluate Pharma Mar's Dehydrodidemnin B (DDB) to modulate the immune system to fight HIV infection. The in vitro studies will evaluate the drug's effect on modulation of peripheral lymphocytes, and will study DDB's potential to inhibit apoptosis as a therapeutic strategy to maintain higher levels of immune cells to fight HIV. ...